Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylalphaman SCHEMBL2447680 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2444941 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2554532 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2447696 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2447683 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2447224 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL93660 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2449290 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL21518298 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2444306 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406477-B | Synthesis of sugar monoethers comprising long alkyl chains and their use as surfactants | 特雷奥斯淀粉及甜味剂比利时公司 | 2021-03-30 | — | — | CN | claimed |
| US-10442830-B2 | Synthesis of monoethers of sugar comprising a long alkyl chain and uses thereof as a surfactant | TEREOS STARCH & SWEETENERS BELGIUM (BE) | 2019-10-15 | — | — | US | claimed |
| EP-3227308-B1 | SYNTHESIS OF SUGAR MONOETHERS WITH A LONG ALKYL CHAIN AND THEIR USE AS SURFACTANTS | TEREOS STARCH & SWEETENERS BELGIUM (BE) | 2018-10-10 | — | — | EP | claimed |
| US-20180265533-A1 | SYNTHESIS OF MONOETHERS OF SUGAR COMPRISING A LONG ALKYL CHAIN AND USES THEREOF AS A SURFACTANT | Tereos Starch & Sweetners Belgium (BE) | 2018-09-20 | — | — | US | claimed |
| CN-107406477-A | The synthesis of sugared monoether comprising long alkyl chain and its purposes as surfactant | 特雷奥斯淀粉及甜味剂比利时公司 | 2017-11-28 | — | — | CN | claimed |
| CN-107835636-B | Antibacterial composition comprising isomeric mixtures of monosaccharide alkyl monoacetals or monosaccharide alkyl monoethers | 特雷奥斯淀粉及甜味剂比利时公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107406477-B | Synthesis of sugar monoethers comprising long alkyl chains and their use as surfactants | 特雷奥斯淀粉及甜味剂比利时公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10537103-B2 | Antibacterial composition containing an isomer mixture of monosaccharide alkyl monoacetals or monoethers | TEREOS STARCH & SWEETENERS BELGIUM (BE) | 2020-01-21 | — | — | US | disclosed |
| US-10442830-B2 | Synthesis of monoethers of sugar comprising a long alkyl chain and uses thereof as a surfactant | TEREOS STARCH & SWEETENERS BELGIUM (BE) | 2019-10-15 | — | — | US | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3492483-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2002103103-A2 | FLUORINE-CONTAINING COMPOUNDS AND POLYMERS DERIVED THEREFROM | HONEYWELL INTERNATIONAL INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102758-A1 | FLUORINE-CONTAINING COMPOUNDS AND POLYMERS DERIVED THEREFROM | HONEYWELL INTERNATIONAL, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-5783678-A | HYDROPHILIC | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-07-21 | — | — | US | disclosed |
| EP-0755951-A2 | Acrylic ester derivative and producing process of the same and acrylic-ester-based polymer | NIPPON SHOKUBAI CO., LTD. (JP) | 1997-01-29 | — | — | EP | disclosed |
| EP-0394496-B1 | GLYCOSIDE DERIVATIVES, POLYMERS CONTAINING GLYCOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE OF SAID POLYMERS | NIPPON FINE CHEMICAL CO (JP) | 1995-08-23 | — | — | EP | disclosed |
| US-5173554-A | Hydrophilic, biocompatibility | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1992-12-22 | — | — | US | disclosed |
| US-5164492-A | Acrylic ester polymers with pendant glycoside groups, blood compatibility, antifogging agents | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| EP-0394496-A1 | GLYCOSIDE DERIVATIVES, POLYMERS CONTAINING GLYCOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE OF SAID POLYMERS | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10537103-B2 | Antibacterial composition containing an isomer mixture of monosaccharide alkyl monoacetals or monoethers | GNE, MGAM, GALE | MAPK1 1931/4885LGALS8 513/4885LGALS3 290/4885 |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, GUSB | MAPK1 4188/4885LGALS8 879/4885LGALS3 449/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | MAPK1 4188/4885LGALS8 879/4885LGALS3 449/4885 |
| US-10442830-B2 | Synthesis of monoethers of sugar comprising a long alkyl chain and uses thereof as a surfactant | TREH, C9, GALE | MAPK1 4336/4885LGALS8 218/4885LGALS3 1051/4885 |
| US-20180265533-A1 | SYNTHESIS OF MONOETHERS OF SUGAR COMPRISING A LONG ALKYL CHAIN AND USES THEREOF AS A SURFACTANT | TREH, C9, GALE | MAPK1 4336/4885LGALS8 218/4885LGALS3 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.